Introduction {#s1}
============

The SOXF group (SOX7, −17 and −18) of transcription factors (TFs) are key regulators of endothelial cell differentiation during development ([@bib10]; [@bib4]; [@bib19]; [@bib28]; [@bib3]; [@bib15]), and are thus critical for the formation of vasculature. Mutation or deletion of *SoxF* genes compromises arteriovenous specification, blood vascular integrity and lymphangiogenesis, and inhibits tumour growth and metastasis in animal models of cancer ([@bib6]; [@bib45]; [@bib47]; [@bib46]). More recently, high levels of SOX18 have been associated with poor prognosis for cancer in human patients ([@bib9]; [@bib35]; [@bib22]). Pharmacological inhibition of SOX18 protein function therefore presents a potential avenue for management of the vascular response in cancer.

Transcription factors often operate in mutually redundant families, thwarting conventional approaches to developing transcription factor-based therapies. Any attempt to develop pharmaceutically useful SOX18 inhibitors must overcome two obstacles --- first, that SOX18 loss of function is compensated by the action of the remaining SOXF ([@bib19]), and second, that each SOXF factor is likely to have several partners that may themselves act redundantly. To address these challenges, we sought to develop a means of broad-scale functional inhibition of SOX18 transcription factor through the simultaneous interference with multiple SOX18 protein-protein interactions (PPIs).

SOX proteins activate individual target genes by recruiting specific interacting partners ([@bib38]), but only two protein-protein interactions for the SOXF group (SOX18-MEF2C and SOX17-OCT4) have been identified to date ([@bib17]; [@bib21]). We first mapped the SOX18 interactome (the network of SOX18 interacting partners), using a combination of unbiased proteomic technologies. Chromatin immunoprecipitation coupled to mass spectrometry (ChIP-MS) provided a first-pass screen for proteins associated with chromatin-bound SOX18 in human umbilical vein endothelial cells (HUVECs) ([@bib32]), then, ALPHA-Screen resolved SOX18-dependent complexes into pairwise interactions using *in vitro* translated full-length proteins ([Figure 1A](#fig1){ref-type="fig"}) ([@bib33]; [@bib24]; [@bib40], [@bib41]; [@bib12]). ChIP-MS analysis revealed 289 proteins, representing a variety of gene ontology (GO) classes of molecular function, that associate directly or indirectly with SOX18 ([Figure 1B](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A--C](#fig1s1){ref-type="fig"}). To increase our chance of identifying direct interactors, we focused on proteins known to be nucleic acid and/or protein binding ([Figure 1B](#fig1){ref-type="fig"}, purple). From this subset, we chose eight known transcription factors, helicases, co-repressors, RNA binding and DNA-repair molecules ([Figure 1---figure supplement 1A,B](#fig1s1){ref-type="fig"}). Using ALPHA-Screen, we observed that SOX18 interacts with itself, and also forms pairwise interactions with DDX1, DDX17, ILF3, STAT1, TRIM28, and XRCC5 ([Figure 1C](#fig1){ref-type="fig"}, left column '+', [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}).10.7554/eLife.21221.002Figure 1.Mapping of SOX18 interactome and disruption of interactions by Sm4.(**A**) Schematic of the experimental strategy to deconvolute SOX18-dependent protein-protein interactions (PPIs) combining Chromatin immunoprecipitation-mass spectrometry (ChIP-MS) and Amplified Luminescent Proximity Homogeneous Assay (ALPHA-Screen) methods. (**B**) GO-term analysis for molecular function on the 289 proteins identified by SOX18-cMyc ChIP-MS in human umbilical vein endothelial cells (HUVECs). Non-specific interactors found in Myc-tag only transfected cells were subtracted. Proteins with nucleic acid binding or protein binding capacity (purple) were considered for consecutive direct interaction studies to enhance likeness of identifying direct interactors. (**C**) Left column: heatmap representation of SOX18 pairwise PPIs as tested by ALPHA-Screen, on a selection of ChIP-MS SOX18 associated proteins, endothelial transcription factors and positive/negative control proteins. Right column: heatmap representation of **Sm4** activity on SOX18-dependent protein-protein interactions, as tested at 100 μM. Interaction and disruption threshold is indicated in the scale bar by a black line. Levels of interaction and disruption above the threshold are demarked by '+', and below the threshold by '−'. Tagged proteins were expressed in the *Leishmania tarentolae* cell-free protein expression system. (**D**) Representative ALPHA-Screen concentration-response curve for SOX18 PPI disruption by **Sm4**. Data shown are mean ± s.e.m.**DOI:** [http://dx.doi.org/10.7554/eLife.21221.002](10.7554/eLife.21221.002)10.7554/eLife.21221.003Figure 1---figure supplement 1.QC of SOX18 PPIs and effect of **Sm4**.(**A**) Mass spectrometry spectrum for a representative double charged DDX17 peptide with the sequence KAPILIATDVASRG (Muscat ion score 51.6), identified from immunoprecipitation of cMyc-SOX18 with anti-cMyc antibody in HUVECs. (**B**) Coverage of identified peptides of SOX18 and interacting proteins selected from ChIP-MS. (**C**) Amino acid sequence of DDX17, with the identified ChIP-MS peptides indicated in green. (**D**) Typical ALPHA-Screen curve for protein dilution optimization, showing SOX9-SOX9 and SOX18-SOX18. The presence of a peak (hook effect) demonstrates an interaction and represents the ideal protein concentration for consecutive binding studies. Proteins were expressed in the *Leishmania tarentolae* cell-free protein expression system. (**E**) Molecular structure of SOX18 inhibitor **Sm4**.(**F**) ALPHA-Screen concentration-response curves for SOX18 PPI disruption by **Sm4**. Data shown are mean ± s.e.m.**DOI:** [http://dx.doi.org/10.7554/eLife.21221.003](10.7554/eLife.21221.003)10.7554/eLife.21221.004Figure 1---figure supplement 2.Differential disruption of SOXF PPI by **Sm4**.The left panel shows a matrix of protein-protein interactions between SOXF, MEF2C and RBPJ and OCT4 as measured by ALPHAScreen. The right panel shows the effects of 50 µM **Sm4** on PPIs (blue = no PPI/disruption, green/yellow = low PPI/disruption, orange/red = strong PPI/complete disruption, grey = PPI below threshold, **Sm4** effect cannot be determined).**DOI:** [http://dx.doi.org/10.7554/eLife.21221.004](10.7554/eLife.21221.004)

In addition, we studied potential pairwise interactions of 6 well-known TFs able to regulate endothelial cell function (ESR1, NR2F2, RBPJ, SOX7, SOX17 and CTNNB1), and the only identified SOX18 protein partner MEF2C ([@bib17]). The well-characterized SOX9 homo-dimer ([@bib2]) was included as a positive control to validate the ALPHA-Screen signal ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). SOX18 was found to interact with all endothelial transcription factors tested, with the possible exception of SOX17 and CTNNB1, which showed a binding affinity below the arbitrary threshold ([Figure 1C](#fig1){ref-type="fig"}, '-').

Having identified an array of proteins able to interact with SOX18, we then went on to test the activity of a small-molecule compound, **Sm4** ([Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}), on these interactions. **Sm4**, derived from a natural product found in the brown alga *Caulocystis cephalornithos*, was identified in a high-throughput screen for potential SOX18 blockers (Fontaine *et al*., to be published in full elsewhere). We found that **Sm4** significantly disrupted 6 out of the 12 validated SOX18 interactions ([Figure 1C](#fig1){ref-type="fig"}, right column), with IC~50~ values ranging from 3.3 μM for SOX18-SOX18 to 65.9 μM for SOX18-RBPJ dimers ([Figure 1D](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1F](#fig1s1){ref-type="fig"}). To assess a differential effect of **Sm4** on the distinct SOXF members, we explored an additional set of PPIs between all three SOXF proteins and MEF2C, RBPJ and OCT4 ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Like SOX18, SOX7 is able to interact with RBPJ and SOX18 itself, both of which interactions are at least partially disrupted by **Sm4**. We further found that all three SOXF proteins can form a heterodimer with OCT4, whereas only the SOX17-OCT4 interaction is affected by **Sm4**. Importantly, neither SOX7 nor SOX17 have the capacity to form a homodimer, and thus this component of **Sm4** mode of action is highly specific to SOX18-SOX18 interaction. Further corroborating this, SOX9 homodimerization was unperturbed by **Sm4** at up to 200 µM ([Figure 1C,D](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). These results show that **Sm4** selectivity leans towards a subset of SOX18-associated PPIs, but has the capability to interfere with SOX7 or SOX17 protein partner recruitment. This feature of **Sm4** is potentially advantageous in preventing SOXF redundancy mechanism ([@bib19]; [@bib23])

To assess how SOX18 PPI disruption translates into transcriptional dysregulation, we next performed a combination of genome-wide RNA-seq and ChIP-seq analyses in HUVECs. The most common binding motif identified from the SOX18 ChIP-seq peaks corresponds to the previously reported SOX motif 5'-AACAAT-3'([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}) and the validity of this ChIP-seq dataset was further confirmed by GO term analysis and identification of known SOX18 target genes such as *Prox1* and *Vcam1* ([Supplementary file 1a](#SD1-data){ref-type="supplementary-material"}, [Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}) ([@bib10]; [@bib18]). We compared the global transcriptional effect of **Sm4** treatment to DMSO control in SOX18 overexpressing cells ([Figure 2---figure supplement 1C--E](#fig2s1){ref-type="fig"}, [Supplementary file 1b](#SD1-data){ref-type="supplementary-material"}), and overlaid this list of differentially expressed genes with the SOX18 ChIP-seq dataset. Using this overlay, we calculated the distance between the transcription start site (TSS) of a gene and a TF binding event, as a proxy for the likelihood of direct transcriptional regulation. To be able to analyse how this distance is altered by **Sm4**, we established a reference distance between the TSS of a random gene set and SOX18 binding events ([Figure 2A](#fig2){ref-type="fig"}). In parallel, we performed the same analysis for SOX7 (generated in-house), and for all seven transcriptional regulators available from the ENCODE consortium (cMYC, GATA2, c-FOS, c-JUN, CTCF, EZH2, MAX, c-MYC). This allowed us to distinguish between transcriptional targeting of SOX18 and potential off target effects on other endothelial specific transcription factors.10.7554/eLife.21221.005Figure 2.**Sm4** selectively affects SOX18 transcriptional output in vitro.(**A**) Schematic representation of the correlation analysis between genome-wide TF ChIP-seq data and **Sm4** affected genes from transcriptomics data. The chromatin around the transcription start sites (TSS) of **Sm4** affected genes (purple) was investigated for transcription factor binding peaks (grey), to calculate the 'distance from TSS' to closest binding site for a given transcription factor. This distance from TSS was used as a proxy for the likelihood of transcriptional regulation, and thus make an association between **Sm4** affected genes and transcription factors. Included in the analysis where the ChIP-seq peaks of SOX18 and SOX7, and of all transcription factors available from the Encode consortium (GATA2, c-FOS, c-JUN, CTCF, EZH2, MAX and c-MYC), performed in HUVECs. A random group of genes was analysed as a control distribution as would be found by chance. (**B**) **Sm4** affected genes were grouped into down-regulated (**Sm4**-down), unaffected (**Sm4-**unchanged) and up-regulated (**Sm4**-up). The plots show the cumulative distribution of the distance between the TSS of **Sm4** affected genes (purple line, absolute fold change ≥2) and the closest genomic location of binding sites for SOX18, and control transcription factors SOX7 and GATA2. The median distance from the TSS of differentially expressed genes to the nearest binding event of a given transcription factor was compared to the median distance that is expected by chance from a random gene set (green line). **Sm4** down regulated genes are significantly closer (bold) to the SOX18 peaks, but not to SOX7 or GATA2 peaks.**DOI:** [http://dx.doi.org/10.7554/eLife.21221.005](10.7554/eLife.21221.005)10.7554/eLife.21221.006Figure 2---figure supplement 1.Transcriptome-wide analysis of **Sm4** selectivity in vitro.(**A**) Top motif identified from SOX18 ChIP-seq peaks (MEME software) performed in HUVECs. (**B**) UCSC browser view of representative ChIP-seq peaks (arrowheads) for known SOX18 target genes *VCAM* and *PROX1*. (**C**) Conditions for transcriptome-wide analysis of **Sm4**. Differential expression (DE) was calculated using DEseq2 in SOX18 overexpressing HUVECs, between vehicle DMSO (SOX18oe) and cells that received 25 μM **Sm4** (**Sm4**) (**D**) Principal component analysis of quadruplicate RNA-seq samples. Replicates samples from same condition (control, SOX18oe, **Sm4**) cluster together. (**E**) Plot showing a comparison between DESeq2 and edgeR methods, marking significance of DE genes between SOX18oe and **Sm4** conditions. Transcripts with a DESeq2 Log2 Fold Change ≥ 1 or ≤ −1 (dashed lines) were considered for further analysis. (**F**) The distance between **Sm4** affected genes (purple) and the closest genomic location of binding sites a given transcription factor, plotted as cumulative distribution. The median distance from the TSS of differentially expressed genes to the nearest binding event of a transcription factor binding event was expressed as a ratio over the median distance that is expected by chance (random genes, green).**DOI:** [http://dx.doi.org/10.7554/eLife.21221.006](10.7554/eLife.21221.006)10.7554/eLife.21221.007Figure 2---figure supplement 2.c-JUN motifs are enriched in SOX18 binding sites.(**A**) HOMER motif analysis on SOX18 ChIP-seq peaks revealed an enrichment of the c-JUN motif 5'-TGAC/GTCA-3'. (**B**) ALPHA-Screen binding curve for SOX18-c-JUN and SOX18-SOX18 (positive control), demonstrating that c-JUN has the capacity to directly interact with SOX18 in vitro. Proteins were expressed in the *Leishmania tarentolae* cell-free protein expression system.**DOI:** [http://dx.doi.org/10.7554/eLife.21221.007](10.7554/eLife.21221.007)10.7554/eLife.21221.008Figure 2---figure supplement 3.**Sm4** does not interfere with SOX9 or SOX17 activity in vitro.(**A**) Cell based reporter assay for SOX9 homodimer activity. COS-7 cell were transfected with *Sox9* and *Col2a1:luc* reporter construct. *Sox9* overexpression caused a \>8 fold induction of *Col2a1* activation. No change was observed at high concentration of **Sm4**. (**B**) Cell based reporter assay for SOX17 activity ([@bib36]). Bovine Aortic Endothelial Cells (BAECs) were transfected with *pTK-β-gal* (pTK) or *ECE1-TK-β-gal* (ECE1) reporter, measuring endogenous activity of SOX17 (ECE1-only). No change was observed at any of the tested concentration. Numbers on x-axis are **\[Sm4\]** in μM.**DOI:** [http://dx.doi.org/10.7554/eLife.21221.008](10.7554/eLife.21221.008)

The cumulative SOX18 peak-to-TSS distance demonstrated that, overall, SOX18 peaks are 3.6 fold closer (p-value\<0.001) to the TSS of **Sm4** down-regulated genes than to randomly distributed TSSs ([Figure 2B](#fig2){ref-type="fig"}, top left). These results are an indirect indication that the **Sm4** affected genes are dysregulated through a specific effect on SOX18 transcriptional activity. This correlation was not observed for 7 of the other transcription factors tested ([Figure 2B](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1F](#fig2s1){ref-type="fig"}, [Supplementary file 1c](#SD1-data){ref-type="supplementary-material"}), signifying that **Sm4** does not have an off-target effect on these TFs activity. Interestingly, the TSS of **Sm4** down-regulated genes were 2.05 fold closer to c-JUN binding events (p-value=0.011, [Supplementary file 1c](#SD1-data){ref-type="supplementary-material"}). Although only mildly significant, this could suggest possible co-regulation by SOX18 and c-JUN on this subset of **Sm4** down-regulated genes. Indeed, analysis of known motifs in SOX18 ChIP-seq peaks revealed an over-representation of c-JUN binding motifs (3.23% of SOX18 peaks, p-value=1e-302) and ALPHA-Screen analysis further established that SOX18 and c-JUN could physically interact ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). We found that the expression levels of the other TFs tested were unaltered by **Sm4** treatment ([Supplementary file 1c](#SD1-data){ref-type="supplementary-material"}). This is an important observation because it demonstrates that there was no bias introduced by an off-target modulation of the transcript levels for these transcription factors in presence of **Sm4**.

To address the issue of potential transcriptional off-target effects of **Sm4** on SOX TF family members we focused on closely related SOXF and SOXE proteins. **Sm4** did not affect the transcriptional activity of either SOX17 or SOX9 proteins at any tested concentration (≤50 μM) in cell-based reporter assays ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}) ([@bib36]; [@bib26]). Together, these results provide strong evidence that **Sm4** selectively targets SOX18-mediated transcription over other key endothelial transcription factors and SOX proteins.

To investigate whether **Sm4** is also able to perturb Sox18 transcriptional activation in vivo, we used the *tg*(*−6.5kdrl:eGFP*) transgenic zebrafish reporter line, previously validated as a readout for the combined activity of Sox7 and Sox18 ([@bib7]). We treated these larvae at 20 hr post fertilization (hpf) and observed that **Sm4** treatment significantly reduced SOX18-dependent *egfp* transcript levels (61%), similar to the effects of combined *sox7/18* depletion using morpholino oligonucleotides (MO) ([Figure 3A,B](#fig3){ref-type="fig"}). Importantly, these zebrafish embryos developed normally and we found no evidence of toxicity.10.7554/eLife.21221.009Figure 3.**Sm4** blocks SoxF transcriptional activity in vivo.(**A**) Lateral brightfield (top) and fluorescent (bottom) images of 60 hpf zebrafish larvae carrying the tg(*−6.5kdrl:eGFP*) SoxF reporter. Treatment was initiated at late stage (20 hpf) with either DMSO (negative control) or 1 μM **Sm4**, or larvae were injected with morpholinos against both *sox7* and *sox18* (dMO *sox7/18*). Fluorescence intensity is shown as heatmap. Scale bar 200 μm (**B**) qRT-PCR analysis on *gfp* transcripts levels in treated tg(*−6.5kdrl:eGFP*) larvae and *sox7/18* morphants, showing reduction of activity on this transgene. (**C**) Lateral view of zebrafish larvae carrying the tg(*Dll4in3:eGFP*) SoxF/Notch reporter that harbors multiple binding sites for Rbpj and SoxF transcription factors. Larvae were injected with a morpholino against *rbpj* and/or treated with 2 μM **Sm4** from 13 hpf. (**D**) qRT-PCR analysis on *gfp* transcripts in tg(*Dll4in3:eGFP*) larvae, showing repression of combined SoxF/Notch activity in the **Sm4**-treated larvae. (**E**) Quantitation of embryonic lethality in larvae, treated with **Sm4** or DMSO control from early stage (16 hpf) until 72 hpf. (**F**) Penetrance of vascular phenotype (arteriovenous shunting) in 48 hpf larvae treated with 1.5 µM **Sm4** from 16 hpf. (**G**) Penetrance of circulation defect in 48 hpf larvae treated with 1.5 µM **Sm4** from 16 hpf. (**H**) qRT-PCR analysis of endogenous endothelial transcript levels at 48 hpf in larvae treated with 1.5 µM **Sm4** at 16 hpf, relative to DMSO control (dotted line). Data shown are mean ± s.e.m. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.21221.009](10.7554/eLife.21221.009)10.7554/eLife.21221.010Figure 3---figure supplement 1.Sox9 activity is not perturbed by treatment in vivo.(**A**) Timeline of treatment: Zebrafish larvae were treated continuously for four days during chondrogenesis. Medium was refreshed daily throughout the experiment to maintain **Sm4** levels. (**B**) *tg*(*col2a1:YFP)* Sox9 reporter larvae marking cartilage ([@bib29]). YFP levels were unaffected in presence of **Sm4**, and no changes in chondrogenesis were observed. mc: Meckel's cartilage, ch: ceratohyal, hs: hyosymplectic. (**C**) qRT-PCR of *yfp* transcript levels in DMSO control and **Sm4** treated larvae at a series of stages throughout chondrogenesis.**DOI:** [http://dx.doi.org/10.7554/eLife.21221.010](10.7554/eLife.21221.010)10.7554/eLife.21221.011Figure 3---figure supplement 2.**Sm4** interferes with SoxF activity in vivo.(**A**) Timeline of **Sm4** treatment in zebrafish larvae. Treatment for SOXF reporter gene studies was initiated at 20 hpf, while for the phenotypic studies treatment was initiated at precedes that for, to act during the right developmental window for arteriovenous specification. (**B**) Lateral view and transverse section of the trunk region of DMSO control and **Sm4**-treated *tg(fli1:eGFP,−6.5kdrl:mCherry)* larvae. Control DMSO larvae formed a distinctly separated dorsal aorta (DA) and posterior cardinal vein (PCV). In **Sm4**-treated larvae, the DA was constricted and/or fused to the PCV (arrowheads). Whole mount in situ hybridization against arterial marker *efnb2a* shows reduced expression and compromised formation of the DA and in **Sm4**-treated larvae at 48 hpf (arrows). Sections were DAPI stained (in blue). Scale bar brightfield: 0.5 mm, fluorescent and in situ 25 μm. (**C**) Concentration dependent effect of **Sm4**, showing quantitation for predominant phenotype at 72 hpf: mild (tail curvature), medium (dilation of the PCV) or severe (arteriovenous defect and/or circulation defect). Indicated timeframe refers to **Sm4** treatment window and endpoint. (**D**) Quantitation of cardiac edema frequency in larvae treated with **Sm4** (1.5 μM). (**E**) qRT-PCR analysis of Sox18 dependent *−6.5kdrl:mCherry* and endogenous endothelial transcript levels in **Sm4**-treated larvae relative to DMSO control (dotted line), showing effect on arterial and venous markers at 24 hpf. All expression levels were normalized to expression of endothelial marker *cdh5*. Data shown are mean ± s.e.m. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.21221.011](10.7554/eLife.21221.011)

We then used a second transgenic zebrafish reporter line *tg(Dll4in3:eGFP)*, which harbours a regulatory element located in the intron 3 of *dll4* gene. The activity of this *Dll4in3* enhancer does not fully recapitulate the endogenous *dll4* expression ([@bib44]; [@bib37]), but it does provide a useful tool to study the combinatorial activity of Sox7, Sox18 and the Notch effector Rbpj. Combined genetic interference with *sox7, sox18* and *rbpj* has been shown to abolish *Dll4in3* activation, while single or double MO knockdowns have a much milder effect ([@bib37]). This mild repressive effect was recapitulated by treatment with **Sm4** alone ([Figure 3C,D](#fig3){ref-type="fig"}). In addition, when *rbpj* MO injections at suboptimal dose were combined with **Sm4** treatment, the repressive effect was significantly increased by 11.5% ([Figure 3C,D](#fig3){ref-type="fig"}). These data show that **Sm4** interferes with Sox7/18 and Rbpj co-ordinated activation of the *Dll4in3* enhancer. As a negative control in vivo, we used the Sox9-dependent *tg(col2a1:yfp*) reporter line, and observed that continuous **Sm4** treatment between 2 and 6 days post fertilization did not perturb the transcriptional activity of Sox9 or the process of chondrogenesis ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Together, this supports the proposed mechanism of action for **Sm4** as a selective SOX18 inhibitor in vivo.

To further demonstrate the small molecule inhibition of Sox18 function in vivo, we next investigated whether **Sm4** treatment would be able to cause a vascular phenotype, similar to that of *sox7*/*sox18* genetically disrupted zebrafish ([@bib14]). This phenotype is characterised by an arteriovenous specification defect, with reduced expression levels of arterial markers ([@bib3]; [@bib15]; [@bib34]). We treated zebrafish larvae harbouring the arterial/venous reporter *tg(fli1a:eGFP,−6.5kdrl:mCherry)* with 1.5 μM **Sm4** during the relevant developmental window, starting from 16 hpf ([Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}). These larvae acquired an enlarged posterior cardinal vein (PCV) at the expense of the dorsal aorta (DA) ([Figure 3E--G](#fig3){ref-type="fig"}, [Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}), with arteriovenous shunts and incomplete trunk circulation ([Figure 3---figure supplement 2C,D](#fig3s2){ref-type="fig"}). qRT-PCR analysis of blood vascular markers at 24 and 48 hpf revealed a significant dysregulation of arterial and venous genes in **Sm4**-treated conditions compared to DMSO, particularly *efnb2a, hey1* and *efnb4a* ([Figure 3H](#fig3){ref-type="fig"}, [Figure 3---figure supplement 2E](#fig3s2){ref-type="fig"}).

Due to SoxF redundancy in arteriovenous specification, an A/V malformation phenotype is typically only observed in double loss of Sox7 and Sox18 function. Since **Sm4** appeared to partially interfere with Sox7-Rbpj and Sox7-Sox18 PPIs in vitro, we turned to a Sox7 specific phenotype to assess whether this TF activity was inhibited by **Sm4** *in vivo*. The hallmark of *sox7* genetic disruption is a short circulatory loop in the head formed by the lateral dorsal artery ([@bib32]), resulting in perturbed facial circulation ([@bib14]). In presence of **Sm4,** we observe minor malformation to the LDA reminiscent of a partial Sox7 loss of function phenotype (Author response image 1). However, the blood circulation in the head is unaffected in **Sm4**-treated larvae, signifying that a short circulatory loop has not fully formed. This phenotype supports of the conclusion that Sox7 activity is only partially affected in presence of the small compound. Overall, these results are congruent with the genome-wide inhibitory effects observed in vitro, demonstrating that **Sm4** selectively interfered with the transcriptional activity of Sox18 and SoxF-mediated vascular formation in vivo.

As a final demonstration of the anti-angiogenic potential of **Sm4** in a therapeutically relevant setting, we next assessed its efficacy in a preclinical model of breast cancer. BALB/c mice were inoculated with highly metastatic 4T1.2 mammary carcinoma cells into the mammary fat pad, and three days were allowed for the engraftment of the tumor, after which treatment was initiated with either 25 mg/kg/day of **Sm4**, aspirin or vehicle PBS ([Figure 4A](#fig4){ref-type="fig"}). Aspirin was chosen as a negative control because of the structural similarity to **Sm4**. Daily treatment was maintained for a duration of 10 days, after which the primary tumor was resected and effects on disease latency were monitored ([Figure 4A](#fig4){ref-type="fig"}). As an indirect indication of target engagement, we first confirmed the expression of *Sox18* in the 4T1.2 tumor vasculature by in situ hybridization ([Figure 4B](#fig4){ref-type="fig"}). We next went on to measure **Sm4** bioavailability during the course of the treatment. **Sm4** was consistently detected in blood plasma at two different time points, with a mean concentration increasing over time from 38.3 µg/mL to 55.2 µg/mL ([Figure 4C](#fig4){ref-type="fig"}).10.7554/eLife.21221.012Figure 4.Metastasis and tumor vascularization is suppressed by **Sm4** treatment.(**A**) Timeline of mouse model for breast cancer metastasis. 4T1.2 tumor was inoculated at day 0, and resected at day 12. **Sm4** (25 mg/kg/day), Aspirin (25 mg/kg/day) or vehicle control (PBS), was administered orally on a daily basis from day 3 to day 12. Independent experiments were carried out to assess survival and metastatic rate. (**B**) Blood plasma concentrations of **Sm4** during the course of the treatment scheme (day 7 and day 12) indicate good systemic delivery of the drug. (**C**) Expression of *SOX18* in the vasculature of the tumor as shown by in situ hybridization. Scale bar 100 μm. (**D**) Survival of the mice was monitored (n = 6--12 mice per group). Improved survival in **Sm4**-treated mice over both vehicle control and aspirin was analysed by Log-rank test (p\<0.001). (**E**) No significant differences were found in tumor size at any stage. (**F**) Metastatic tumor nodules on the surface of the lungs were quantified at day 28, before any of the vehicle control or **Sm4**-treated animal had succumbed to the cancer burden. Data shown are mean ± s.e.m of 12--14 mice per group. (**G**) Vascular density was investigated on 300 μm sections of whole tumors. Bright field images show the overall morphology of the tumor (outlined by dashed line) and presence of red blood cells, marking the main blood vessels and haemorrhagic areas (asterisks). Scale bar 1 mm. (**H**) Double immunofluorescence staining for endothelial specific markers ERG and Endomucin (EMCN) reveals the vascular patterning and penetration in the intra- and peri- tumoral regions. Left: whole tumor section (scale bar 1 mm), middle and right: blow-up of boxed regions (scale bar 200 µm). (**I**) Quantitation of EMCN volume (blood vessel density) and ERG-positive nuclei (number of endothelial cells) of n = 6 tumours per condition. Each data point represents the average of 3--4 representative regions (boxed areas in panel H) per tumor. Mean ± s.e.m for both conditions are shown. \*p\<0.05, \*\*p\<0.01.**DOI:** [http://dx.doi.org/10.7554/eLife.21221.012](10.7554/eLife.21221.012)10.7554/eLife.21221.013Figure 4---figure supplement 1.**Sm4** efficacy is not a result of surgery-induced inflammation.4T1.2 tumor was inoculated at day 0, and surgery was performed at day 12, without resecting the tumor (n = 6). (**A**) Survival (n = 6) was monitored in PBS vehicle control mice and **Sm4**-treated mice (25 mg/kg/day). No differences were observed (Log-rank test). (**C**) No significant differences were found in tumor size at any stage before or after sham surgery.**DOI:** [http://dx.doi.org/10.7554/eLife.21221.013](10.7554/eLife.21221.013)10.7554/eLife.21221.014Figure 4---figure supplement 2.Penetrance of blood vessels into 4T1.2 tumors is impaired by **Sm4**.Brightfield images of serial vibratome sections (300 μm) from a whole 4T1.2 mammary tumor for mice treated with PBS vehicle or **Sm4**. Main blood vessels and haemorrhagic areas are distinctive in red.**DOI:** [http://dx.doi.org/10.7554/eLife.21221.014](10.7554/eLife.21221.014)10.7554/eLife.21221.015Figure 4---figure supplement 3.**Sm4**-treated mice have decreased tumor vascular density.Immunofluorescent staining for ERG and Endomucin (EMCN) on tumor sections. Two representative regions for both vehicle PBS and **Sm4** are shown. Detailed blow-up shows distinct nuclear staining for ERG, and membranous endothelial staining for EMCN. Quantitation of endothelial cells number and vascular volume was performed in Imaris on images with identical XYZ dimensions. Thresholds were chosen to accurately capture total EMCN+ vasculature and total ERG+ nuclei (ERG count and EMCN volume in yellow).**DOI:** [http://dx.doi.org/10.7554/eLife.21221.015](10.7554/eLife.21221.015)10.7554/eLife.21221.016Figure 4---figure supplement 4.**Sm4** treatment disrupts tumour-induced lymphangiogenesis.Lymphatic vessels images of serial vibratome sections (200 μm) from a whole 4T1.2 mammary tumor for mice treated with PBS vehicle or **Sm4** (25 mg/kg/day). Immunofluorescence for lymphatic specific markers PROX1 and Podoplanin (PDPN) and vascular EC marker Endomucin (EMCN) reveals the vascular patterning and penetration in the intra- and peri- tumoral regions. Whole tumor section for the control group (top panels), and for **Sm4** treated group (bottom panels). Quantitation of PDPN^+^ lymphatic vascular area (density, top graph) and PROX1^+^ nuclei (number of lymphatic endothelial cells, bottom graph) of n ≥ 6 tumours per condition. Scale bar left: 0.5 mm, right: 0.1 mm. Mean ± s.e.m for both conditions are shown. \*\*p\<0.01, \*\*\*p\<0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.21221.016](10.7554/eLife.21221.016)

PBS vehicle- or aspirin-treated mice succumbed to the 4T1.2 tumor burden with a median latency of 33 and 34 days respectively ([Figure 4D](#fig4){ref-type="fig"}), whereas **Sm4**-treated mice had a significant increase in their overall survival with a median latency of 44 days (p-value\<0.01). To further investigate what could cause such an effect, the size of the tumors was monitored during the treatment, as well as the formation of spontaneous lung metastases. While the size of the primary tumor was unchanged by **Sm4** treatment ([Figure 4E](#fig4){ref-type="fig"}), we found a 67% reduction in the mean number of lung metastases at day 28 after tumor inoculation ([Figure 4F](#fig4){ref-type="fig"}).

To rule out any contribution by an inflammatory response as a result of surgery, we replicated the study by performing a sham surgery, without excising the tumor ([Figure 4---figure supplement 1A,B](#fig4s1){ref-type="fig"}). This approach confirmed that during the post-surgical period, primary tumor growth was unperturbed by **Sm4** treatment and demonstrated that the combined effects of **Sm4** with surgery-induced inflammation is unlikely to be responsible for the increased survival.

In order to establish a correlation between the metastatic rate and a tumor induced vascular response, we investigated the blood vessel density in the intra-tumoral and peri-tumoral regions ([Figure 4G](#fig4){ref-type="fig"}, [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). Whole tumors were sectioned, and brightfield microscopy revealed an overall reduction in blood vessel coverage, as indicated by the presence of red blood cells ([Figure 4G](#fig4){ref-type="fig"}, asterisks). Further analysis using immunofluorescent staining for endothelial cell markers ERG (nuclear) and Endomucin (EMCN, membranous), showed a significant decrease in the number of endothelial cells (48%, p-value\<0.05), as well as the volume of the blood vessels (55%, p-value\<0.01) in the tumors of **Sm4**-treated mice ([Figure 4H,I](#fig4){ref-type="fig"}, [Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). Using lymphatic specific markers PROX1 and podoplanin (PDPN), we also assessed the effect of **Sm4** on the tumor induced lymphangiogenic response, and found that the density of the tumor associated lymphatic vessels was greatly reduced (65%, p-value\<0.01) in treated conditions, as well as the number of lymphatic endothelial cells (70%, p-value\<0.001) ([Figure 4---figure supplement 4](#fig4s4){ref-type="fig"}). This lymphatic response to **Sm4**-treatment is consistent with that of SOX18 loss of function during lymphatic spread of solid cancers ([@bib6]) Together, this demonstrates that **Sm4** improved the outcome of induced breast cancer by interfering with tumor-induced neo-vascularization and associated metastasis.

Induction of angio- and lymphangiogenesis is a hallmark of solid cancer, and is a critical step towards enabling tumor metastatic dissemination. Conventional approaches to target transcription factors have focused on interfering with oncogenes that are dysregulated to promote tumor cell transformation ([@bib13]; [@bib20]; [@bib31]; [@bib48]). Here, we validate a novel complementary strategy that relies on targeting a developmental transcription factor from the host vasculature that can facilitate metastatic spread. Our results provide a proof of concept that targeting the transcription factor SOX18 with **Sm4** is an effective molecular strategy to interfere with the metastatic spread in a pre-clinical model of breast cancer.

Materials and methods {#s2}
=====================

Experimental reproducibility {#s2-1}
----------------------------

All data and statistical analysis in this study were generated from at least three independent experiments unless indicated otherwise. Technical replicates were included in every experiment to reduce background noise and detect technical anomalies. Samples of distinct experimental conditions were not exposed to any specific method of randomization, and groups were assessed under non-blinded conditions.

Plasmid preparation for cell-free expression {#s2-2}
--------------------------------------------

The genetically encoded tags used here are enhanced GFP (GFP), mCherry (Cherry) and cMyc (myc). The proteins were cloned into the following cell free expression Gateway destination vectors respectively: N-terminal GFP tagged (pCellFree_G03), N-terminal Cherry-cMyc (pCellFree_G07) and C-terminal Cherry-cMyc tagged (pCellFree_G08) ([@bib11]).The Open Reading Frames (ORFs) corresponding to the human SOX7 (BC071947), SOX17, RBPJ (BC020780) and MEF2C (BC026341) were sourced from the Human ORFeome collection version 1.1 and 5.1 or the Human Orfeome collaboration OCAA collection (Open Biosystems) as previously described and cloned at the ARVEC facility, UQ Diamantina Institute. The entry clones pDONOR223 or pENTR201 vectors were exchanged with the ccdB gene in the expression plasmid by LR recombination (Life Technologies, Australia). The full-length human *SOX18* gene was synthesized (IDT) and the transfers to vectors was realized using Gateway PCR cloning.

Cell-free protein expression {#s2-3}
----------------------------

The translation competent *Leishmania tarentolae* extract (LTE) was prepared as previously described ([@bib33]; [@bib24]). Protein pairs were co-expressed by adding 30 nM of GFP template plasmid and 60 nM of Cherry template plasmid to LTE and incubating for 3 hr at 27°C.

ALPHA-Screen assay {#s2-4}
------------------

The ALPHA-Screen Assay was performed as previously described ([@bib41]), using the cMyc detection kit and Proxiplate-384 Plus plates (PerkinElmer). A serial dilution of each sample was measured. The LTE lysate co-expressing the proteins of interest was diluted in buffer A (25 mM HEPES, 50 mM NaCl). For the assay, 12.5 μL (0.4 μg) of Anti-cMyc coated Acceptor Beads in buffer B (25 mM HEPES, 50 mM NaCl, 0.001% NP40, 0.001% casein) were aliquoted into each well. This was followed by the addition of 2 μL of diluted sample and 2 μL of biotin labeled GFP-Nanotrap in buffer A. The plate was incubated for 45 min at RT. Afterward, 2 μL (0.4 μg) of Streptavidin coated Donor Beads diluted in buffer A, were added, followed by incubation in the dark for 45 min at RT. The ALPHA-Screen signal was obtained on an Envision Multilabel Plate Reader (PerkinElmer), using the manufacturer's recommended settings (excitation: 680/30 nm for 0.18 s, emission: 570/100 nm after 37 ms). The resulting bell-shaped curve is an indication of a positive interaction, while a flat line reflects a lack of interaction between the proteins. The measurement of each protein pair was repeated a minimum of three times using separate plates. The Binding Index was calculated as: $BI = ~\left\lbrack \frac{I - I_{neg}}{I_{ref} - I_{neg}} \right\rbrack x~100$

For each experiment, I is the highest signal level (top of the hook effect curve) and I~neg~ is the lowest (background) signal level. The signals were normalized to the I~ref~ signal obtained for the interaction of SOX18 with itself.

For PPI disruption assay, protein pairs expressed in LTE were incubated for 1 hr with 100 μM **Sm4** or DMSO alone (0.7% DMSO final). 100 μM **Sm4** or DMSO was also added to buffer B. PPI disruption was calculated as$:~\left( {1 - \frac{I_{Sm4}}{I_{DMSO}}} \right)x~100$.

For IC~50~ determination, the assay was identical but a dilution range of **Sm4** was used (0.3 to 300 μM). Percentage of interaction was calculated as:$~\frac{I_{Sm4}}{I_{DMSO}}~x~100$. Data from at least three independent experiments were fitted in GraphPad Prism (RRID: [SCR_007370](https://scicrunch.org/resolver/SCR_007370)) version 6.0 using 3-parameter non-linear regression.

Cell culture and transfection {#s2-5}
-----------------------------

COS-7 cells were purchased from ATCC (CRL-1651, RRID: [CVCL_0224](https://scicrunch.org/resolver/CVCL_0224)) cultured at 37°C, 5% CO~2~ in DMEM (Life technologies, 11995) with added FBS, sodium pyruvate, L-glutamine, penicillin, streptomycin, non-essential amino acids and HEPES (*N*-2-hydroxyethylpiperazine-*N\'*−2-ethanesulfonic acid). COS-7 cells were transfected for 4--6 hr, and incubated for another 24 hr before lysis and luciferase assay (Perkin Elmer, 6016711). Human umbilical vein endothelial cells (HUVECs) were purchased from Lonza Australia (CC-2519A). HUVEC for ChIP-MS, ChIP-seq and RNA-seq analyses were transfection for 7 hr and incubated another 14 hr. During small molecule treatment, cells were grown in medium containing low serum (0.4% FBS). HUVECs were cultured at 37°C, 5% CO~2~ in EGM-2 media supplemented according to the EGM-2 bullet kit instruction (Lonza, CC-3162). Cells for were grown in 35 mm dishes to 80--90% confluency, and transfected with plasmid mouse pSG5 *Sox18*, plasmid pSG5 *cMyc-Sox18*, or plasmid *cMyc* using X-tremegene 9 DNA transfection reagent (Roche, 06365787001) according to the manufacturer's instructions. All cell lines were tested negative for mycoplasma contamination.

Chromatin immunoprecipitation {#s2-6}
-----------------------------

ChIP experiments were performed as previously described ([@bib39]). Immunoprecipitation was performed using Anti-cMyc (Cell Signaling, \#2276, RRID: [AB_2314825](https://scicrunch.org/resolver/AB_2314825)) on HUVECs overexpressing cMyc-tagged SOX18.

ChIP-seq and analysis {#s2-7}
---------------------

Following IP, DNA amplification was performed using TruSeq ChIPseq kit (Illumina, IP-202--1012), using 0.5 µM of the universal reverse PCR primer and the forward PCR primer containing the index sequence of choice in 50 µL 1 x NEBNext High-Fidelity PCR Master Mix (New England Biolabs, M0541). The number of PCR cycles ranged from 13 to 18, depending on the ChIP efficiency. The PCR product was purified using AMPure beads (1.8 vol) and eluted in 20 µL of resuspension buffer (Tris-Acetate 10 mM pH 8). The library was quantified using the KAPA library quantification kit for Illumina sequencing platforms (KAPA Biosystems, KK4824) and 50 bp single end reads were sequenced on a HiSeq2500 following the manufacturer's protocol. Illumina fastq files were mapped to the GRCh37/UCSC hg19 genome assembly using bowtie, and peaks were called using MACS version 2.1.0. using input. To avoid false positive peaks calling due to the cMyc epitope, ChIP-seq with the cMyc epitope only were performed in parallel to SOX18-cMyc ChIP-seq and peaks called in these experimental conditions were substracted to the peaks called in the SOX18-cMyc conditions. Genomic Regions Enrichment of Annotations Tool (GREAT, RRID: [SCR_005807](https://scicrunch.org/resolver/SCR_005807))) was used to analyse the functional significance of cis-regulatory regions. ChIP-seq data are available in the ArrayExpress database ([www.ebi.ac.uk/arrayexpress](http://www.ebi.ac.uk/arrayexpress), RRID: [SCR_002964](https://scicrunch.org/resolver/SCR_002964)) under accession number E-MTAB-4480 (SOX7) and E-MTAB-4481 (SOX18).

ChIP-MS (RIME) {#s2-8}
--------------

ChIP-MS experiments were performed as previously described ([@bib32]). Peptides common between SOX18-cMyc and the negative control (cMyc-only) were binned and only peptides that were uniquely detected in the SOX18-cMyc transfected cell were considered for analysis.

RNA-seq and analysis {#s2-9}
--------------------

Quadruplicate samples were processed for whole transcriptome sequencing using TruSeq stranded total RNA library prep kit (Illumina). Reads were mapped to the hg19 reference human genome using STAR aligner ([@bib5]), and only uniquely aligned reads were considered. Transcripts were assigned to genes using htseq_count (HTseq package) ([@bib1]), and differential expression was calculated using DEseq2 ([@bib27]). Genes with adjusted p-value\<0.05 were considered significant.

Differentially expressed genes were identified between **Sm4**-treated and DMSO control in SOX18 over-expressing cells, and separated in up-regulated and down-regulated (DOWN) genes. The locations of their transcription start sites (TSS) were correlated to the locations of transcription factors binding events that are available from the ENCODE consortium (RRID: [SCR_006793](https://scicrunch.org/resolver/SCR_006793)), and from the SOX18 and SOX7 ChIP-seq experiment we performed in this study. To ensure that the TSSs were independent, a TSS was allowed to only be assigned to 1 ChIP-seq peak. Transcripts with ≥2 fold absolute fold change (log2FC ≥ 1 or ≤ −1) were included for distance to TSS analysis. The median distance between the TSSs and binding events was compared to the expected distance of a set of randomly selected genes to obtain the median ratio. The control set of genes was selected from the pool of genes expressed in HUVECs so that they had a similar distribution of expression levels. To ensure that no bias was introduced by potential co-regulation of genes by SOX18 and any other transcription factor analysed, we subtracted genes with SOX18 peaks from the analyses for other transcription factors. The reverse analysis was also performed, subtracting genes containing c-JUN peaks from the analysis for SOX18. RNA-seq data are available in the ArrayExpress database ([www.ebi.ac.uk/arrayexpress](http://www.ebi.ac.uk/arrayexpress)) under accession number E-MTAB-4511.

Quantitative RT-PCR {#s2-10}
-------------------

Total RNA was extracted using RNeasy mini kit (Qiagen, 74106) according to the manufacturers protocol, including on column DNA digestion. cDNA was synthetised from 1 µg of purified RNA using the high capacity cDNA reverse transcription kit (Life Technologies, 4368813). Amplification and quantitation of target cDNA was performed in technical triplicate of at least three biological replicates using the SYBR green (Life Technologies, 4312704) methods. Reactions were run in 10 µL in 384-well plates using the ViiA 7 Real-Time PCR system. Housekeeper genes (*β-actin* for *tg(Dll4in3:eGFP)*, *ef1α* for *tg(−6.5kdrl:eGFP)*, *chd5* for *tg(fli1a:eGFP, −6.5kdrl:mCherry)*, *RPL13* and *GAPDH* for HUVECs) were selected based on the stability of their expression throughout the set of experimental conditions, or chosen on grounds of their vascular expression to normalize to endothelial cell content. Primer efficiencies were calculated using LinRegPCR, and amplification data was analysed using ViiA7 software and the Q-gene PCR analysis template.

Zebrafish aquaculture and analysis {#s2-11}
----------------------------------

Zebrafish were maintained as previously described ([@bib16]), and all procedures involving animals conformed to guidelines of the animal ethics committee at the University of Queensland (IMB/030/16/NHMRC/ARC/HF) or were approved by local ethical review and licensed by the UK Home Office (PPL 30/2783 and PPL 30/3324). The *tg(−6.5kdrl:eGFP)*, *tg(fli1a:eGFP,−6.5kdrl:mCherry)* and *tg(Dll4in3:GFP)* were previously described ([@bib37]; [@bib7]; [@bib25]).

Dechorionation was performed by treatment with 25 µg/mL or 5 µg/mL pronase for 2 hr, or overnight, respectively. Zebrafish larvae were anesthetized using 0.01% tricaine. Representative larvae were embedded in 0.5% low-melting point agarose and imaged with the Zeiss LSM 710 confocal microscope.

Zebrafish in situ hybridization and sectional analysis {#s2-12}
------------------------------------------------------

Wholemount zebrafish (28 and 48 hpf) in situ hybridization was performed as previously described ([@bib43]) with probe templates for *dab* ([@bib42]) and *ephrinB2a* ([@bib8]). Yolk sac was removed prior to addition of in 70% glycerol. For transverse sections, whole larvae where embedded in 4% agarose, sectioned at 150 µm using the Leica VT1000 S vibrating microtome. Imaging was performed on the Olympus BX-51 brightfield microscope (ISH), and Zeiss LSM 510 confocal microscope. For fluorescent images, larvae were DAPI-stained before embedding.

Small molecule treatment and morpholino injections {#s2-13}
--------------------------------------------------

All treatment with putative small molecule inhibitors, and corresponding control conditions, were performed in the presence of low concentration of DMSO (≤1% v/v) to achieve reliable homogeneous solutions, and were prepared from 10 mM DMSO stock. For cell culture, small molecules were added to fresh media directly following transfection and cells were grown in this media until time-point of cell harvesting. For in vivo experiments involving zebrafish, compound treatment was initiated at the designated timepoints by replacing the media, and media + compound was refreshed daily for the duration of the experiment. PTU treatment (0.003%) was done in parallel with the small molecules to block pigment formation when necessary. Previously published and validated morpholino oligomers against *sox7*, *sox18* ([@bib15]) and *rbpj* ([@bib37]) were micro-injected into single cell zebrafish zygotes at 5 ng for experiments performed with *tg(6.5kdrl:eGFP)* and *tg(fli1a:eGFP,−6.5kdrl:mCherry),* and 0.125--0.15 pmol suboptimal concentrations for experiments performed with *tg(Dll4in3:eGFP*).

Mice and mouse model {#s2-14}
--------------------

BALB/c wild-type (WT) were purchased from Walter and Eliza Hall Institute for Medical Research and used between the ages of 6 and 10 weeks. Mouse 4T1.2 mammary carcinoma cells were cultured in complete RPMI with 10% FBS in a 5% CO~2~ incubator. 5×10^4^ 4T1.2 tumor cells were inoculated into the fourth mammary fat-pad of BALB/c WT mice as previously described ([@bib30]). Briefly, on day three after tumor implantation, mice were orally gavaged daily for 10 days with 25 mg/kg of body weight **Sm4**, aspirin or vehicle PBS. Tumor size was measured with a digital caliper as the product of two perpendicular diameters. Blood plasma was collected from mice on day 7 and 12, and **Sm4** concentrations were analyzed using a 4000 Qtrap LC-MS/MS system mass spectrometer. On day 12, mice were anesthetised to surgically remove primary tumor, or mice were put through surgery procedure with no excision of the primary tumor, and the wound was closed with surgical clips. Tumors were collected in formalin for histology. Lungs were harvested on day 28 and fixed in Bouin's solution for 24 hr and metastatic tumor nodules were counted under a dissection microscope. Survival of the mice was monitored in experiments where the lungs were not harvested. Groups of 6 to 14 mice per experiment were used for experimental tumor assays, to ensure adequate power to detect biological differences. All experiments were approved by the QIMR Berghofer Medical Research Institute Animal Ethics Committee (P1505).

For quantitation of the vasculature in the tumors, fixed tissues were embedded in 4% agarose and sectioned all the way through at 300 µm on a Leica VT1000 S vibrating microtome. Sections were collected on glass slides and imaged for bright field analysis on the penetration of perfused vessels. Subsequently, immunofluorescent staining was performed on sections using anti-mouse Endomucin (cat\# sc-53941, RRID: [AB_2100038](https://scicrunch.org/resolver/AB_2100038)), ERG (cat\# ab92513, RRID: [AB_2630401](https://scicrunch.org/resolver/AB_2630401)), PROX1 (AngioBio cat\#11--002, RRID: [AB_10013720](https://scicrunch.org/resolver/AB_10013720)) and Podoplanin (AngioBio cat\#11--033, AB_2631191) antibodies. Whole tumor sections were imaged by acquiring a series of images along the z-axis using a 10x objective on a Zeiss LSM 710 confocal microscope. Subsequently, high-resolution images were captured using a 20x objective on 3--4 separate regions from each tumor, to account for heterogeneity of the vascular density within the tumors and minimise bias. Raw image files with identical dimensions (1274.87 µm x 1274.87 µm x 89.05 µm) were loaded into Imaris (Bitplane, RRID: [SCR_007370](https://scicrunch.org/resolver/SCR_007370)), and processed using 'spots' function to count ERG or PROX1- positive nuclei and 'surface' to calculate volume or area of Endomucin or Podoplanin positive vessels. For each tumor (n = 6), counts from the multiple regions were averaged and the data was plotted in Graphpad Prism 6.
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###### (A) GO term analysis (PANTHER) on top 5K SOX18 ChIP-seq peaks, reveals over-representation of biological processes, which are in agreement with known roles for SOX18 (e.g. blood vessel morphogenesis, angiogenesis, blood vessel development).

\(B\) Summary of sequencing statistics, listing the sample with the number of the replicate (\#n). Percentage of mapped reads is consistently high across all samples (\>87%). Mapping was performed with STAR aligner ([@bib5]). (C) Summary of endothelial specific TF expression levels and summary of distance from peak to TSS analysis on DE SOX18oe *vs*. **Sm4** genes. A subtraction of SOX18, or cJUN peaks from all TF peaks was performed to reduce overlap bias (column \#2 and \#3). **Sm4** down regulated genes are significantly closer to SOX18 and c-JUN ChIP-seq peaks.

**DOI:** [http://dx.doi.org/10.7554/eLife.21221.017](10.7554/eLife.21221.017)
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Pharmacological targeting of the transcription factor SOX18 delays breast cancer in mice\" for consideration by *eLife*. Your article has been favorably evaluated by Sean Morrison (Senior Editor) and three reviewers, one of whom, Holger Gerhardt (Reviewer \#1), is a member of our Board of Reviewing Editors. The following individual involved in review of your submission has agreed to reveal their identity: Gou Young Koh (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

General Assessment:

The reviewers find your study provides interesting new insights into protein-protein interactions of Sox family member transcription factors and shows convincingly that such interactions can be targeted with small molecules to interfere with good selectivity with transcription in vitro and in vivo. The demonstration of in vivo efficacy of the small molecular inhibitor in both a zebrafish model using transcriptional reporters and in a mouse tumour model in which you find significantly reduced metastasis are particularly remarkable. Together with the comprehensive identification and validation of protein-protein interactions, these results provide a significant advance that the reviewers believe will be of interest to a wider scientific audience.

Major Conclusions:

1\) Despite their similarities Sox family member transcription factors engage in distinct protein-protein interactions.

2\) Sox18 interacts directly with RBPjk and a number of other endothelial transcription factors in endothelial cells to regulate endothelial targets.

3\) Small molecule SM4 (identified in a screen reported elsewhere) shows good efficacy and selectivity to inhibit a subset of the identified Sox18 protein-protein interaction and suppresses target transcription in vivo.

4\) Targeting Sox18 PPI and thus its transcriptional activity is effective in vivo to reduce tumour angiogenesis and metastasis.

Whilst the reviewers find your results supports these major conclusions, they find that the following points should be adequately addressed before publication:

1\) The claim of selectivity of SM4 against Sox18 deserves further investigation, in particular, to clarify if the potentially redundant activity of Sox17 in vascular development is also affected. Also, potential activity against Sox7 should be clarified. You may already have the required data on activity of SM4 against Sox17 and Sox7, in which case adding these to the figure and text, as well as commenting on their implications for the claimed selectivity of SM4 will be sufficient. In case this means you need to repeat experiments, we suggest to limit yourself to any that can be achieved reasonably within 2 months.

2\) The discrepancy between the effects on the *Dll4int3* reporter and endogenous *Dll4* gene expression effects of SM4 need to be clarified. Given that the *Dll4int3* reporter does not contain all regulatory elements of the endogenous *Dll4* gene, it could be that SM4 is more effective against the reporter and other elements still drive endogenous *Dll4*. As you currently don\'t comment on the discrepancy in the text, it is difficult for us to recommend precisely how you should address this issue. We suggest to carefully compare the response of endogenous *Dll4* expression similarly to the dose response you find for the *Dll4* reporter. Given the dynamic nature of *Dll4* expression, it could also be a timing issue, and thus related to the half-life of the drug? A possible experiment in vivo could be to show in situ hybridisation for *Dll4* in WT fish treated with SM4. As *Dll4* levels have a major impact on blood vessel formation also in tumour angiogenesis, and your in vivo mouse experiments show effects on tumour angiogenesis, we feel this needs to be clear in order to understand the action of SM4. This should be possible to address in two months. In case experimental data do not provide a clear answer, please address this issue carefully in text and Discussion.

3\) The mechanism of reduced tumour angiogenesis and metastasis should be adequately discussed and ideally experimentally clarified. Given that the route of metastasis is likely through lymphatics and that Sox18 also regulates lymphangiogenesis, we feel you should consider this as potential mechanism. As you have the expertise in mouse lymphatic analysis from previous studies, we hope you will be able to provide experiments that show whether or not SM4 interferes with tumour lymphangiogenesis through blocking Sox18 function. It will not be necessary to show that this is the definitive cause for changes in metastasis, but we feel that without analysing lymphatics, this work is incomplete. Given that you use a xenograft model, it should be feasible to perform these experiments within the 2 months of revision period.

We hope you will find these comments useful and clear to allow efficient revisions of the essential points. For your information, we also append the full set of reviews below.

*Reviewer \#1:*

This interesting report by Overman et al. presents the functional characterisation of a pharmacological compound targeting the interaction of the transcription factor SOX18 with other proteins. This particular compound, Sm4, was isolated through a high-throughput screen for selective SOX18 inhibitors described fully in an accompanying manuscript that will be published elsewhere. The current manuscript used successive screening by first CHIP MS and then Α screen to map protein+protein interactions of Sox18, and then study in detail the selectivity and inhibitory capacity of the compound Sm4 on SOX18 activity both in vivo and in vitro. The in vivo used the zebrafish model in which Sox18 transcriptional regulation of known vascular genes was investigated in reporter lines and by QPCR. Finally, the authors used a mouse orthotopic mammary tumour model to test efficacy in tumour angiogenesis and metastasis in vivo.

Overall, the work convincingly demonstrates that the approach taken is valid to identify key protein protein interactions of transcription factors, and that targeting these interactions can be achieved with efficacy and some selectivity in vivo.

The work is well written and illustrated, and the major claims appear supported by the data. Having said that, there are a number of issues that should be addressed to further clarify the claim of the specificity of Sm4\'s inhibition of SOX18 direct protein interactions and its role in inhibiting Sox18-mediated vascular formation in vivo. Critically, the authors test specificity and efficacy of Sm4 in vivo first in the Dll4int3 reporter line, but endogenous Dll4 seems unaffected. This is left uncommented and raises questions regarding the mechanism at play.

Furthermore, whereas the arteriovenous development deficit is clearly demonstrated in fish, the rest of the vascular changes in fish and in mouse tumours don´t match with what would be expected if Sox18 and RBPJ activity was reduced in blood endothelium. Furthermore, whilst these vascular changes are well demonstrated in the tumours, the actual reason for reduced lung metastasis is not addressed. Surprisingly, despite having originally identified Sox18 as key regulator of lymphatic development, and given that metastatic spread from mammary tumours is largely driven by lymphatics, the authors did not look at and comment on tumour associated lymphatic changes and the potential effects of Sm4.

Given that the work primarily aims to establish the approach to target PPI for transcriptional regulation in vivo, the latter point may not necessarily have to be addressed experimentally, but should at least be discussed. More pertinent to the overall claims are the remaining questions on specificity.

Please find further detailed comments below:

1\) Given the redundancy of Sox18 and Sox17 in the context of vascular development, the authors should include OCT4 interaction in their functional analysis of the effects of SM4 on both SOX17/OCT4 (reported interaction) and SOX18/OCT4.

2\) -- Could the authors describe what the arbitrary threshold used to define interaction in [Figure 1C](#fig1){ref-type="fig"} is? Were there any physiological or chemical reasons used in defining it?

3\) -- Could the authors comment about the significant proximity between c-FOS and EZH2 binding sites and the transcriptional start site of up-regulated genes following Sm4 treatment? Are their transcriptional activities significantly affected by Sm4 treatment?

4\) The authors describe that \"\[...\] we calculated the distance between the transcription start site (TSS) of a gene and a TF binding event, as a proxy for the likelihood of direct transcriptional regulation\". But later mention that, in regard to this analysis, \"The results indicate that Sm4 affected genes are dysregulated through a direct effect on SOX18 transcriptional activity\". Given the \'proxy\' nature of this experiment, I believe the claim could be turned down to better reflect the fact that this is a rather indirect indication of specificity.

5\) Could the authors provide evidence that Sm4 does not affect SOX18 DNA-binding role? This particular piece of data is required to show that Sm4 role on Sox18 role in vivo indeed relies on affecting SOX18 interaction with other proteins rather that in its ability to bind to DNA.

6\) Does Sm4 affect the transcriptional activity of Sox7? In [Figure 3](#fig3){ref-type="fig"}, could the authors please include a combined treatment with MO-sox18/Sm4 and MO-sox7/Sm4 to further demonstrate Sm4 specificity within SoxF factors. In addition, the authors should also include a MO-sox7/Mo-rbpj/Sm4 and MO-sox18/MO-rbpj/Sm4 controls in [Figure 3C](#fig3){ref-type="fig"}.

7\) As mentioned in the overall assessment, does Sm4 treatment affect the pre-existing lymphatic vasculature in area surrounding the tumour? In addition, is neo-lymphangiogenesis affected?

*Reviewer \#2:*

In this paper, the authors describe a specific inhibitor of the transcription factor SOX18, a known regulator of vascular development. Using a combination of in vitro/ChIP-seq/in vivo experiment, they build a nice scientific approach to develop an anti-angiogenic drug able to inhibit tumor development. They start from an elegant experiment of ChIP-MS to isolate nuclear factors interacting with SOX18 presumably on chromatin. They test also interaction of SOX18 with several transcription factors obtained from the ChIP-MS to validate the protein-protein interaction and also to measure the effect of a small molecule sm4, describe in another manuscript, on these interactions. A ChIP-seq experiment coupled to RNA-seq shows, using a good bio-informatics approach, the specificity at the genomic level of Sm4 on the SOX18 transcriptional activity. The authors also predict a possible relationship of SOX18 with C-Jun.

The second part of the manuscript, presents the in vivo validation of action of Sm4 on the genetic pathway controlled by SOX18 followed by experiments in mouse showing the inhibition of tumor vascularization by Sm4. To my knowledge, it is one of the first studies showing the development of a drug able to block specifically the activity of a SOX protein.

*Reviewer \#3:*

Although the roles of SoxF members including Sox18 are crucial for formation and maintenance of vascular system, exactly how they form the protein complex for their transcriptional activities remains poorly elucidated. The present work may be the first report unveiling the entity of the proteins that physically interact with Sox18 and the interaction between SoxF members. Thus, this work provides a significant scientific advance by deciphering the mechanism of transcriptional regulation which are critical for vascular morphogenesis. Some additional in vivo data would improve the integrity of the manuscript for publication.

1\) The authors demonstrated that a natural compound Sm4 effectively inhibits the transcriptional activity of Sox18 in molecular and cellular levels. Moreover, the inhibitory effect of Sm4 was verified in vivo by using zebrafish reporter lines (*tg(-6.5kdrl:eGFP)* and *tg(Dll4in3:eGFP)*), in which arteriovenous specification defects were assessed. All these zebrafish systems are known to be modulated by the cooperation of Sox7 and Sox18 rather than by Sox18 alone. Therefore, the authors should be cautious to claim the effect of Sm4 is dependent solely on Sox18 inhibition based on these complicated in vivo systems. This potential complexity should be discussed.

2\) Sm4 appears to have a potential as an oral therapeutic agent to treat cancer as they have shown that Sm4 treatment reduced lung metastasis in a mouse orthotopic mammary tumor model. Reduced tumor angiogenesis is suggested as a working mechanism for the reduced tumor metastasis in this work. On the other hand, vascular destabilization is well-known to induce tumor metastasis. Additional analysis of tumor vessels integrity may provide clues as to how the vascular changes induced by Sm4 administration are associated with decreased metastasis.

3\) The authors showed Sox18 expression in tumor vessels to rationalize the inhibitory effect of Sm4 on tumor angiogenesis. It has been previously reported that tumor angiogenesis/lymphangiogenesis was suppressed in Sox18-knockout mice (JNCI 2006); thus, pharmacological blockade of Sox18 can indeed reduce tumor angiogenesis. However, there is a possibility that Sm4 can inhibit tumor angiogenesis and tumor growth by affecting molecules other than Sox18. This possibility could be tested by administering Sm4 to Sox18-knockout mice bearing tumors, since the effect of Sm4 on Sox18 will be abolished in this mouse model.

10.7554/eLife.21221.028

Author response

*\[...\] Whilst the reviewers find your results supports these major conclusions, they find that the following points should be adequately addressed before publication:*

*1) The claim of selectivity of SM4 against Sox18 deserves further investigation, in particular, to clarify if the potentially redundant activity of Sox17 in vascular development is also affected. Also, potential activity against Sox7 should be clarified. You may already have the required data on activity of SM4 against Sox17 and Sox7, in which case adding these to the figure and text, as well as commenting on their implications for the claimed selectivity of SM4 will be sufficient. In case this means you need to repeat experiments, we suggest to limit yourself to any that can be achieved reasonably within 2 months.*

We acknowledge that selectivity is a crucial consideration for an inhibitor to be of use as a chemical probe or therapeutic. Therefore, we have broken down the matter regarding selectivity into three key aspects: PPI disruption, inhibition of transcriptional actvity, and SOXF loss of function phenocopy in vascular development.

PPI disruption selectivity

To further investigate the selectivity of Sm4 between all three SOXF family members (SOX7, -17 and -18) we have performed additional PPI analyses by ALPHAScreen, focusing on the recruitment of RBPJ (relevant in a vascular context as demonstrated by Sacilotto et al. 2013), MEF2C (only known SOX18 interactor, Hosking et al. 2001) and the SOX17 protein partner OCT4 (key determinant in endoderm specification, Jauch et al. 2011 and Aksoy et al. 2013).

[Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} (new): This in vitro protein-protein interaction analysis revealed that SOX18 has the capacity to selectively form a hetero-dimer with SOX7 and RBPJ whereas SOX17 does not interact with other SOXF proteins, nor does it interact with RBPJ or MEF2C. The interaction with RBPJ is conserved between SOX18 and SOX7 (left panel). Sm4 has the ability to interfere with SOX7-SOX18 heterodimer formation (IC~50~ 19.6 μM, [Figure 1---figure supplement 1F](#fig1s1){ref-type="fig"}) and partially disrupts SOX7-RBPJ interaction. In addition, as suggested by reviewer \#1, we have investigated the effects of Sm4 on SOXF-OCT4 protein-protein interaction. Results show that Sm4 has the potential to disrupt SOX17-OCT4 interaction but not SOX18-OCT4 or SOX7-OCT4.

Data shown in [Figure 1](#fig1){ref-type="fig"} of the manuscript combined with new supplemental results (new [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}) suggest that Sm4 selectivity is mostly towards SOX18 but has some potential to interfere with SOX7- or SOX17-dependent PPI (in the high micro-molar range \[Sm4\] 50-100 μM). Our observations indicate that this inhibitory effect predominantly occurs in the scenario where SOX18 and the other SOXF protein share a particular interactor.

Of note the interaction between SOX17 and OCT4 (POU5F1) is not relevant to endothelial cell biology since this transcription factor is not expressed by endothelial cells as shown by transcripts analysis from FANTOM5 database ([Author response image 1](#fig5){ref-type="fig"}), and from the RNA-seq data in HUVECs generated in-house ([Figure 2](#fig2){ref-type="fig"}). Correspondingly, OCT4 was not identified in SOX18 ChIP-MS experiments performed in endothelial cells. We can therefore exclude that the SOXF-OCT4 interaction -- and disruption thereof -- contributes to the observed effects of Sm4-treatment in endothelial cells.10.7554/eLife.21221.018Author response image 1.Snapshot of FANTOM5 database, showing (absence of) *OCT4* transcript levels in arterial, venous and lymphatic endothelial cell types.**DOI:** [http://dx.doi.org/10.7554/eLife.21221.018](10.7554/eLife.21221.018)

It is often challenging for small molecules to achieve selective targeting between closely related proteins, such as those within the SOXF group of transcription factors (SOX7,-17 and 18). The small molecule that we describe acts in such a way that SOX18-dependent protein complexes are disrupted. Each SOXF protein has its distinct 'primary' function mediated by specific sets of PPIs, which bestows opportunities for selective inhibition. However, these 3 TFs also do have certain PPIs in common, which could explain their overlaping function in the context of rescue mechanism. Redundancy has been shown for SOX7, 17 and 18 protein that can act interchangeably to rescue the loss of function of one another within the F-group (Hosking et al. 2009). The fact that Sm4 has the potential to inhibit a subset of SOX7, SOX17 or SOX18--dependent PPIs is an advantage to prevent any potential redundancy mechanism.

The claims regarding the specific targeting of SOX18 by Sm4 has been reworded more carefully in light of these new data (fifth paragraph of the main text). The additional PPI analysis has been added as new [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}.

Off-target profiling

To include a wider analysis of Sm4 specificity towards SOX18, we have performed an unbiased off target investigation using a CEREP/Eurofins/ Panlabs profiling panel. This is shown by a new data set we have now included in the revised version of our companion manuscript (standard profiling panel, new Table S3 Fontaine et al. Cell Chemical Biology). Proteins tested on this panel are representative of various biological processes, such as: GPCRs, kinases, nuclear receptors, HDACs, sirtuins and membrane receptors. CEREP uses as a cut off 50% inhibition to flag any potential off target effect. This panel analysis with Sm4at 10 μM did not flag any non-specific binding out of 36 protein tested.

Selectivity on transcriptional interference

To assess other SOX proteins' activity that could be potentially affected by Sm4 we have included *SOX9* and SOX17 as negative controls throughout the study. We show that Sm4 does not perturb:

*SOX9* homodimer formation ([Figure 1](#fig1){ref-type="fig"})

*SOX9* transcriptional activity in cell-based assay in vitro ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"})

*SOX9*-induced Col2a1 transactivation in zebrafish larvae ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"})

SOX17-induced ECE1 transactivation ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}).

The analysis of ChiPseq/RNAseq data sets ([Figure 2](#fig2){ref-type="fig"}) further demonstrates that Sm4 is specific to SOX18 interference amongst endothelial TFs, including SOX7.

Selectivity on vascular development- phenotypic output

The current data set based on two SoxF reporter assays in zebrafish ([Figure 3](#fig3){ref-type="fig"}), combined with the partial phenocopy of *sox7/18* double morphants/knockout ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}) and the ALPHAScreen data, demonstrates the ability of Sm4 to block Sox18 activity in vivo. Since Sm4 has the ability to interfere partially with Sox7/RBPJ interaction, we further investigated whether Sm4 could directly interfere with Sox7 function in zebrafish. For this approach, we used as a readout the phenotypic outcome of the *sox7* KO zebrafish line (Hermkens et al. Development 2015) and compared it to Sm4-induced phenotype.

The hallmark of *sox7* genetic disruption in zebrafish is a short circulatory loop in the head with no circulation in the trunk and tortuous lateral dorsal artery (LDA). In presence of Sm4, we observe a partial phenocopy of Sox7 loss of function characterized by a mild vascular defect in the LDA ([Author response image 2](#fig6){ref-type="fig"}). The observed Sm4-induced phenotype supports the conclusion that Sox7 activity is partially affected in presence of the small compound. However, the treated larvae fully establish blood circulation in the head (in contrast to the trunk), and do not form a short circulatory loop typical of Sox7 loss of function. This is now included in the text of the revised manuscript (eleventh paragraph of the main text). Of note, it is possible that the minor LDA phenotype is be secondary to the arteriovenous fusion phenotype.10.7554/eLife.21221.019Author response image 2.**Sm4**-treatment causes mild malformations to the lateral dorsal aorta (LDA), reminiscent of partial interference with Sox7 function.Head circulation is unaffected by Sm4.**DOI:** [http://dx.doi.org/10.7554/eLife.21221.019](10.7554/eLife.21221.019)

Lastly, the use of various zebrafish model system to assess the effects of Sm4 in vivo during development ([Figure 3](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} and [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}) strongly suggest that Sm4 has no conspicuous effect on other SOX TFs. Interference (chemical or genetic) with developmental transcription factors at the stages we investigated would results in severe defects, while we observe that Sm4-treated zebrafish larvae develop normally, with the exception of the phenotype associated with perturbed SOXF function (malformation of axial blood vessels).

*2) The discrepancy between the effects on the Dll4int3 reporter and endogenous Dll4 gene expression effects of SM4 need to be clarified. Given that the Dll4int3 reporter does not contain all regulatory elements of the endogenous Dll4 gene, it could be that SM4 is more effective against the reporter and other elements still drive endogenous Dll4. As you currently don\'t comment on the discrepancy in the text, it is difficult for us to recommend precisely how you should address this issue. We suggest to carefully compare the response of endogenous Dll4 expression similarly to the dose response you find for the Dll4 reporter. Given the dynamic nature of Dll4 expression, it could also be a timing issue, and thus related to the half-life of the drug? A possible experiment* in vivo *could be to show in situ hybridisation for Dll4 in WT fish treated with SM4. As Dll4 levels have a major impact on blood vessel formation also in tumour angiogenesis, and your* in vivo *mouse experiments show effects on tumour angiogenesis, we feel this needs to be clear in order to understand the action of SM4. This should be possible to address in two months. In case experimental data do not provide a clear answer, please address this issue carefully in text and Discussion.*

We agree with the interpretation regarding the discrepancy in terms of activity comparing *Dll4int3* synthetic reporter line versus endogenous *dll4* expression. It is often the case that synthetic enhancers -- containing only a discrete number of regulatory elements -- are more responsive to a subset of regulators. For example, the synthetic *-6.5kdrl* promoter that we use the assess SoxF activity is highly responsive to Sox7 and Sox18 activity, while the endogenous gene *kdrl (flk1*) is not (Duong et al. 2014). We also observe this for this synthetic promoter fragment using both Morpholino approaches and Sm4-treatment ([Figure 3](#fig3){ref-type="fig"}).

Work by Sacilotto et al. demonstrated that deletion of the Sox binding motif in this Dll4int3 enhancer fragment leads to a loss of transcriptional activation, which demonstrates that this transgene is dependent on SoxF activity (Sacilotto et al. 2013). This does not mean that the endogenous regulation of *dll4* solely relies on SoxF activity. It has been shown that another *dll4* enhancer *Dll4int12* is also required to drive proper expression of this gene in endothelial cells (Wyth et al. 2013). This enhancer relies on Ets and Rbpj combinatorial mode of action and it is unknown whether SoxF are at play to modulate this particular regulatory element.

In the context of vascular development in the zebrafish and mouse, Sacilotto et al. showed that individual loss of SoxF proteins or Rbpj has little effect on *Dll4in3* activation, and correspondingly, we show in our study that Sm4 treatment slightly affects this transgene in zebrafish ([Figure 3](#fig3){ref-type="fig"}). A more profound effect was observed when Sm4-treatment was combined with *rbpj* morpholino injections. Overall, we do not claim that Sox18 is a master regulator of *dll4* expression, nor do we suggest that Sm4 is a chemical regulator of *dll4* transcription. Instead, we utilize *Dll4int3* synthetic enhancer activity as a readout for on-target Sox18 inhibition. To make this clear to the reader, we have adjusted the text accordingly (tenth paragraph of the main text).

In order to explore the effect of **Sm4** on *dll4* endogenous transcriptional activation we have performed in situ hybridization on DMSO ctrl and Sm4 treated zebrafish larvae, as suggested ([Author response image 3](#fig7){ref-type="fig"}).

This analysis shows that the effect of Sm4 on the endogenous *dll4* transcript is not as profound as the effects observed on *Dll3int3* enhancer activity. This result is consistent with the qRT-PCR data analysis of *dll4* in Sm4-treated zebrafish larvae ([Figure 4G](#fig4){ref-type="fig"}), which also show a very mild reduction in the overall *dll4* transcript levels.10.7554/eLife.21221.020Author response image 3.Effect of Sm4 on endogenous *dll4* transcript in 27 hpf zebrafish larvae.Both the dorsal aorta and intersomitic vessels (ISV) were labeled by *dll4* ish probe. In presence of Sm4(1 μM) ISV show a mild decrease of signal intensity.**DOI:** [http://dx.doi.org/10.7554/eLife.21221.020](10.7554/eLife.21221.020)

*3) The mechanism of reduced tumour angiogenesis and metastasis should be adequately discussed and ideally experimentally clarified. Given that the route of metastasis is likely through lymphatics and that Sox18 also regulates lymphangiogenesis, we feel you should consider this as potential mechanism. As you have the expertise in mouse lymphatic analysis from previous studies, we hope you will be able to provide experiments that show whether or not SM4 interferes with tumour lymphangiogenesis through blocking Sox18 function. It will not be necessary to show that this is the definitive cause for changes in metastasis, but we feel that without analysing lymphatics, this work is incomplete. Given that you use a xenograft model, it should be feasible to perform these experiments within the 2 months of revision period.*

We greatly appreciate this suggestion, given the reported role of Sox18 in lymphangiogenesis and the contribution of lymphatic vasculature to the malignancy of many types of solid tumour. To address this request, we have quantified the tumour-induced lymphangiogenic response in absence or presence of Sm4. Immunofluorescence staining of 4T1.2 tumour sections was performed for lymphatic specific markers PROX1 and Podoplanin along with the blood vascular marker endomucin. Results show that both lymphatic vessel density and number of lymphatic endothelial cells is reduced in presence of Sm4 treatment. This lack of lymphatic outgrowth in presence of the small molecule is likely to contribute to the decrease in lung metastasis and improved disease latency. This result is now included in the manuscript as new [Figure 4---figure supplement 4](#fig4s4){ref-type="fig"} and in the main text (fifteenth paragraph).

[^1]: These authors contributed equally to this work.
